Small-Molecule PROTACS: New Approaches to Protein Degradation.

Angewandte Chemie (International ed. in English) (2016-01-13)
Momar Toure, Craig M Crews
摘要

The current inhibitor-based approach to therapeutics has inherent limitations owing to its occupancy-based model: 1) there is a need to maintain high systemic exposure to ensure sufficient in vivo inhibition, 2) high in vivo concentrations bring potential for off-target side effects, and 3) there is a need to bind to an active site, thus limiting the drug target space. As an alternative, induced protein degradation lacks these limitations. Based on an event-driven model, this approach offers a novel catalytic mechanism to irreversibly inhibit protein function by targeting protein destruction through recruitment to the cellular quality control machinery. Prior protein degrading strategies have lacked therapeutic potential. However, recent reports of small-molecule-based proteolysis-targeting chimeras (PROTACs) have demonstrated that this technology can effectively decrease the cellular levels of several protein classes.

材料
货号
品牌
产品描述

Sigma-Aldrich
(S,R,S)-AHPC-pyrimidine-piperazine-PEG1-NH2 hydrochloride
Sigma-Aldrich
(S,R,S)-AHPC-pyridine-PEG1-piperazine hydrochloride
Sigma-Aldrich
C5 Lenalidomide-pyrimidine-piperazine-PEG1-NH2 hydrochloride, ≥95%
Sigma-Aldrich
C5 Lenalidomide-PEG6-Butyl NH2 hydrochloride, ≥95%
Sigma-Aldrich
Pomalidomide-PEG3-NH2 hydrochloride, ≥95%
Sigma-Aldrich
(S,R,S)-AHPC-PEG1-NH2 hydrochloride, ≥95%
Sigma-Aldrich
(S,R,S)-AHPC-PEG2-butyl CO2H, ≥95%
Sigma-Aldrich
(S,R,S)-AHPC-PEG3-NH2 hydrochloride, ≥95%
Sigma-Aldrich
Pomalidomide-C3-CO2H, ≥95%
Sigma-Aldrich
(S,R,S)-AHPC-methylamino-PEG1-NH2 hydrochloride
Sigma-Aldrich
Pomalidomide-dipiperazine-NH2 hydrochloride, ≥95%
Sigma-Aldrich
(S,R,S)-AHPC-PEG2-NH2 hydrochloride, ≥95%
Sigma-Aldrich
Pomalidomide-PEG2-CO2H, 95%
Sigma-Aldrich
(S,S,S)-AHPC hydrochloride, ≥97%
Sigma-Aldrich
Pomalidomide-pyridine-PEG1-piperazine hydrochloride
Sigma-Aldrich
C5 Lenalidomide-pyridine-PEG1-piperazine hydrochloride, ≥95%
Sigma-Aldrich
Pomalidomide-PEG2-NH2 hydrochloride, ≥95%
Sigma-Aldrich
Pomalidomide-PEG1-NH2 hydrochloride, ≥95%
Sigma-Aldrich
Pomalidomide-PEG1-CO2H, ≥95%
Sigma-Aldrich
Pomalidomide-benzyl-piperazine hydrochloride
Sigma-Aldrich
(S,R,S)-AHPC-benzyl-piperazine hydrochloride
Sigma-Aldrich
C5 Lenalidomide-benzyl-piperazine hydrochloride
Sigma-Aldrich
N-Methylated pomalidomide, ≥98%
Sigma-Aldrich
Pomalidomide-C3-NH2 hydrochloride, ≥95%
Sigma-Aldrich
C5 Lenalidomide-PEG3-NH2 hydrochloride, ≥95%
Sigma-Aldrich
Pomalidomide-PEG4-CO2H
Sigma-Aldrich
(S,R,S)-AHPC-PEG5-NH2 hydrochloride
Sigma-Aldrich
(S,R,S)-AHPC-piperazine-pyridine-alkyne-NH2 hydrochloride
Sigma-Aldrich
Pomalidomide-PEG6-NH2 hydrochloride, ≥98%
Sigma-Aldrich
Pomalidomide-PEG1-Alkyne, ≥98%

社交媒体

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

科研、开发、生产。

作为生命科学行业的全球领先供应商,我们致力于为科研、生物技术开发和生产,以及制药药物疗法开发和生产提供各类解决方案和服务。

© 2021年版权归德国达姆施塔特默克集团(Merck KGaA)及/或其附属公司所有。版权所有。

未经许可,严禁复制本网站上的任何资料。